CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
ADVL1615 COG A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors Pediatric CIRB
ADVL1622 COG Phase 2 Trial of XL184 (Cabozantinib); an Oral Small-Molecule Inhibitor of Multiple Kinases; in Children and Young Adults with Refractory Sarcomas; Wilms Tumor; and Other Rare Tumors Pediatric CIRB
ADVL1712 COG A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND#142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Pediatric CIRB
ADVL1823 COG Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Pediatric CIRB
ADVL18P1 COG An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation Pediatric CIRB
AEPI05N1 COG Carcinogen Metabolism; DNA Repair; Parental Exposures and Retinoblastoma: A Groupwide Non-Therapeutic Study Pediatric CIRB
AEPI07N1 COG Genetic Susceptibility Factors in the Etiology of Neuroblastoma also known as Neuroblastoma Epidemiology in North America (NENA): A Groupwide Non-Therapeutic Study Pediatric CIRB
AEWS0521 COG A Randomized Phase II Study of Bevacizumab (NSC 704865; BB-IND# 7921) Combined with Vincristine; Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma Pediatric CIRB
AEWS0621 COG Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma Pediatric CIRB
AEWS07B1 COG A COG Study for Collecting and Banking Ewing Sarcoma Specimens Pediatric CIRB